1257294-60-2 Usage
Uses
Used in Pharmaceutical Industry:
2-(1-((5-Chloro-7-Morpholinothiazolo[5,4-d]pyriMidin-2-yl)Methyl)piperidin-4-yl)propan-2-ol is used as a potential drug candidate for its potential therapeutic effects. 2-(1-((5-Chloro-7-Morpholinothiazolo[5,4-d]pyriMidin-2-yl)Methyl)piperidin-4-yl)propan-2-ol's unique structure and functional groups may contribute to its biological activity, making it a valuable asset in the development of new medications for various health conditions.
Used in Medicinal Research:
In the field of medicinal research, 2-(1-((5-Chloro-7-Morpholinothiazolo[5,4-d]pyriMidin-2-yl)Methyl)piperidin-4-yl)propan-2-ol serves as a chemical probe for studying the mechanisms of action and potential applications of similar compounds. Its complex structure allows researchers to explore its interactions with biological targets, which could lead to the discovery of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1257294-60-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,7,2,9 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1257294-60:
(9*1)+(8*2)+(7*5)+(6*7)+(5*2)+(4*9)+(3*4)+(2*6)+(1*0)=172
172 % 10 = 2
So 1257294-60-2 is a valid CAS Registry Number.
1257294-60-2Relevant articles and documents
Potent and highly selective benzimidazole inhibitors of PI3-kinase delta
Murray, Jeremy M.,Sweeney, Zachary K.,Chan, Bryan K.,Balazs, Mercedesz,Bradley, Erin,Castanedo, Georgette,Chabot, Christine,Chantry, David,Flagella, Michael,Goldstein, David M.,Kondru, Rama,Lesnick, John,Li, Jun,Lucas, Matthew C.,Nonomiya, Jim,Pang, Jodie,Price, Stephen,Salphati, Laurent,Safina, Brian,Savy, Pascal P. A.,Seward, Eileen M.,Ultsch, Mark,Sutherlin, Daniel P.
, p. 7686 - 7695 (2012/10/29)
Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3Kδ. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3Kδ inhibitors. Instead, the selectivity of the compounds for inhibition of PI3Kδ relative to other PI3K isoforms appears to be due primarily to the strong interactions these inhibitors are able to make with Trp760 in the PI3Kδ binding pocket. The pharmacokinetic properties and the ability of compound 5 to inhibit the function of B-cells in vivo are described.